These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7044357)

  • 1. Residual pancreatic function in insulin dependent diabetics.
    Glatthaar C; Beaven DW; Donald RA; Smith JR; Espiner EA
    Aust N Z J Med; 1982 Feb; 12(1):43-7. PubMed ID: 7044357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics.
    Madsbad S; Krarup T; Reguer L; Faber OK; Binder C
    Diabetologia; 1981 May; 20(5):530-4. PubMed ID: 7026327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
    Faber OK; Binder C
    Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-peptide measurement and its clinical usefulness: a review.
    Bonser AM; Garcia-Webb P
    Ann Clin Biochem; 1981 Jul; 18(Pt 4):200-6. PubMed ID: 7025733
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.
    Hendriksen C; Faber OK; Drejer J; Binder C
    Diabetologia; 1977 Dec; 13(6):615-9. PubMed ID: 338408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-cell function and metabolic control in insulin treated diabetics.
    Madsbad S; McNair P; Faber OK; Binder C; Christiansen C; Transbøl I
    Acta Endocrinol (Copenh); 1980 Feb; 93(2):196-200. PubMed ID: 6990673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diurnal profiles of intermediary metabolites in insulin-dependent diabetes and their relationship to different degrees of residual B-cell function.
    Madsbad S; Faber OK; Binder C; Alberti KG; Lloyd B
    Acta Diabetol Lat; 1981; 18(2):115-21. PubMed ID: 7018146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion.
    Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P; Gerich JE
    Diabetes; 1983 Feb; 32(2):134-41. PubMed ID: 6337896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free insulin, C-peptide and glucagon profiles in insulin dependent diabetes mellitus.
    Scott RS; Espiner EA; Donald RA; Ellis MJ
    Aust N Z J Med; 1980 Apr; 10(2):146-50. PubMed ID: 6992759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-peptide response to glucagon in young diabetics.
    Juang JH; Huang BY; Huang HS; Lin JD; Huang MJ
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):579-83. PubMed ID: 2677232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function].
    Li X; Zhou ZG; Qi HY; Chen XY; Huang G
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Aug; 29(4):419-23. PubMed ID: 16134594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic hormone secretion in chronic pancreatitis without residual beta-cell function.
    Larsen S; Hilsted J; Tronier B; Worning H
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):357-64. PubMed ID: 2899369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes.
    Madsbad S; Faber OK; Binder C; McNair P; Christiansen C; Transbøl I
    Diabetes; 1978; 27 Suppl 1():262-4. PubMed ID: 344117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy.
    Lauritzen T; Binder C; Faber OK
    Acta Paediatr Scand Suppl; 1980; 283():81-5. PubMed ID: 7010905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pancreatic beta-cell function in Itsenko-Cushing disease].
    Slavnov VN; Komissarenko IV; Eremenko NI
    Vrach Delo; 1983 Nov; (11):79-82. PubMed ID: 6362198
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of insulin secretory capacity in diabetes mellitus.
    Horwitz DL; Rubenstein AH
    Hum Pathol; 1979 May; 10(3):257-66. PubMed ID: 381153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of glucose profiles, insulin antibody levels and beta cells secretory patterns in non-obese Ugandan diabetic subjects.
    Otim MA
    East Afr Med J; 1988 Jan; 65(1):8-15. PubMed ID: 3046922
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus.
    Gerich JE; Langlois M; Noacco C; Lorenzi M; Karam JH; Korsham PH
    J Clin Invest; 1976 Aug; 58(2):320-5. PubMed ID: 783198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between residual insulin secretion and metabolic stability in type 1 (insulin dependent) diabetes.
    Lutterman JA; Benraad TJ; van 't Laar A
    Diabetologia; 1981 Aug; 21(2):99-102. PubMed ID: 7021291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.